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Objectives: Women of childbearing age with a diagnosis of breast cancer often 
want to conceive a child after treatment. Some reports found that pregnancy does 
not increase the risk of cancer recurrence after successful treatment. These reports 
and positive changes in the survival rates of breast cancer patients can impact the 
decisions of patients and physicians. The goal of this study was to estimate the 
number of women who survived breast cancer and subsequently became preg-
nant and to determine the time between the cancer diagnosis and pregnancy in 
the time periods between 2000-2002 and 2010-2012, respectively. MethOds: This 
retrospective study analysed longitudinal routine care data collected by gynaecolo-
gists in Germany (IMS® Disease Analyzer). Data from women aged 20-45 with a 
pregnancy within 10 years after the first breast cancer diagnosis from 102 gynae-
cological practices in Germany (Disease Analyzer database; 01/1992 to 12/2012) 
were analysed. Results: In the time period 2000-2002, 65 (projected to national 
level: 4615) women became pregnant after a breast cancer diagnosis; this number 
increased to 114 (projected to national level: 8094) between 2010-2012. The mean 
age did not significantly change between 2000-2002 and 2010-2012 (33.8 (SD: 6.0) 
and 34.2 years (SD: 6.1)). The time between the first breast cancer diagnosis and 
pregnancy identification was 896 days (SD: 690) in 2000-2012 and 552 days (SD: 
696) in 2010-2012 (p< 0.01). cOnclusiOns: This retrospective analysis showed 
that the number of pregnancies following breast cancer diagnosis has signifi-
cantly increased in the last 10 years. More over, the time to pregnancy has become 
significantly shorter. This is indicative of the positive and hopeful developments 
for young women affected by breast cancer. Further studies on this important 
research topic are necessary.
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Objectives: About 1 in 8 U.S. women will develop invasive breast cancer during 
their lifetime. Response to treatment varies among women depending on several 
factors. This work identified and prioritized the essential variables to imple-
ment personalized cancer treatment, and determined the feasibility of obtaining 
these variables from available data sources toward a real time clinical decision 
aid. MethOds: A focus group of 10 breast cancer clinicians was conducted to deter-
mine possible variables for inclusion into the clinical dashboard. An electronic 3-cat-
egorical scale (must have, would like to have, unnecessary) survey was conducted 
among a broader group of breast cancer clinicians. Variables were classified by 
category and mention frequency (Mode). The accessibility of these variables from 
two separate cancer care databases was evaluated by data querying, text search and 
electronic chart review and categorized as available, difficult to access, or unavail-
able. Results: Ten clinicians identified 67 possible variables for inclusion into the 
dashboard. According to the broader electronic survey 25 clinicians determined 
39 “must have” variables with 9 patient specific variables (e.g. age at diagnosis, 
comorbidities, hormone replacement use, cancer history); 13 tumor specific vari-
ables (e.g. clinical stage at diagnosis, histologic grade, laterality) and 17 timeline 
related variables (e.g. date and type of surgery, chemo/endocrine/targeted therapies 
received by date, chemotherapy regimen and cycle information, overall survival). 
34 of identified “must have” variables were accessible from at least one of available 
databases. Of the relevant variables five may be difficult to access, including BRCA 
testing and status, performance status, date and site of recurrence, disease free 
survival and treatment delay. cOnclusiOns: Breast cancer clinicians identified 39 
essential variables, the majority of which can be obtained from currently available 
databases and then uploaded into a clinical dashboard to support personalized 
medicine at the point of care for patients with breast cancer.
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Objectives: To indirectly compare the efficacy (progression free survival (PFS)/
time to progression (TTP) and overall survival (OS) of everolimus plus exemes-
tane (EVE+EXE) with fulvestrant in patients with hormone receptor positive, HER2 
negative advanced or metastatic breast cancer. MethOds: A systematic search of 
the Cochrane Library and other resources was undertaken to identify reviews and 
clinical trials reporting interventions for metastatic breast cancer that would allow 
an indirect comparison of fulvestrant and EVE+EXE. A Bayesian fixed effect model 
was used with exemestane adopted as the base treatment for the model because it 
provided the most information in the network. The basic parameters of the model 
are the log hazard ratios with respect to exemestane for PFS/TTP and OS from the 
included studies. In the absence of full networks for TTP/PFS, these outcomes were 
assumed to be the same measure in a disease with short survival times. Results: 
Six trials contributed to a network for PFS/TTP and five to a network for OS. Because 
the comparator treatment was used as the base treatment, a HR > 1 indicates that 
the comparator is less effective than everolimus. For PFS/TTP, EVE+EXE performed 
better than fulvestrant 250mg (HR 2.13 Credible interval (CI):1.72 to 2.63) and 500mg 
(HR 1.69 CI: 1.30 to 2.22). This difference was statistically significant. For OS, EVE+EXE 
performed better than fulvestrant 250mg (HR 1.36 Cl: 0.95 to 1.97) and 500mg (HR 
1.15 Cl: 0.76 to 1.75) but the difference was not statistically significant. A complete 
statistical assessment of heterogeneity for PFS/TTP and OS was not possible because 
of data limitations. cOnclusiOns: EVE+EXE confers better PFS/TTP benefit in HR+ 
HER2-ve metastatic breast cancer when indirectly compared with fulvestrant 250mg 
the colorectal cancer and comparison groups, adjusted for baseline demographic 
and clinical characteristics. Results: A total of 75,208 patients were identified 
for the colorectal cancer and comparison cohorts. After 1:1 PSM, 24,053 patients 
were matched from each group, and the baseline characteristics were proportion-
ate. Patients diagnosed with colorectal cancer had more health care utilization 
including inpatient (20.40% vs. 2.61%, p< 0.01), emergency room (ER) (15.32% vs. 
6.06%, p< 0.01), outpatient (99.60% vs. 64.31%, p< 0.01) and pharmacy visits (88.30% 
vs. 66.20%, p< 0.01). The higher health care utilization resulted in increased health 
care costs, including high inpatient ($9,867 vs. $795, p< 0.01), ER ($158 vs. $61, p< 0.01), 
outpatient ($5,020 vs. $1,585, p< 0.01), pharmacy ($1,345 vs. $523, p< 0.01) and total 
costs ($16,232 vs. $2,903, p< 0.01) for patients diagnosed with colorectal cancer 
compared to patients in the comparison group. cOnclusiOns: Veteran patients 
diagnosed with colorectal cancer incurred significantly higher health care utiliza-
tion and costs over a 1-year period compared to patients without colorectal cancer.
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Objectives: The development of targeted therapies has changed the paradigm of 
cancer management necessitating the use of robust biomarkers to identify eligible 
patients. This study aims to evaluate trends in molecular diagnostic test (MDT) uptake 
across various solid tumors. MethOds: This study used IMS Oncology Analyzer™, a 
patient database collected through a quarterly physician panel survey. This database 
provides comprehensive insight into cancer care. Selected patients were at advanced/
metastatic stages and diagnosed with breast (BC), stomach (SC), non-small cell lung 
cancer (NSCLC) or colorectal cancer (CRC) and receiving chemotherapy. MDT uptake 
was analyzed from time 0 (year of the European Medicines Agency –EMA– approval 
of the associated targeted therapy) until 2012. The analysis was done on 5 EU coun-
tries (France, Germany, Italy, Spain and UK). Results: Trastuzumab was approved 
in HER2+ BC by the EMA in 2000 and had a line extension in 2004. In metastatic 
BC, the proportion of HER2-tested patients in 2004 was 60% (787/1,320) versus 94% 
(1,351/1,430) in 2012. Following further approval in 2010 for use in HER2+ advanced SC, 
HER2-testing grew from 17% (176/1,015) to 50% (501/993) between 2010 and 2012 in this 
population. In the year that Gefitinib gained EMA approval in EGFR+ NSCLC (2009), 8% 
of advanced NSCLC patients (280/3,465) were EGFR-tested. This proportion increased 
to 56% (2,092/3,708) in 2012. Panitumumab and Cetuximab obtained EMA approval for 
KRAS-wild type CRC in 2007 and 2008 respectively. In 2009, 42% (1,183/2,843) of meta-
static CRC patients were K-RAS-tested and 62% (1,782/2,873) in 2012. cOnclusiOns: 
The use of MDTs has become increasingly important in oncology as more targeted 
therapies are launched. While consistent growth in testing is established, differences 
exist in the delay to achieving routine testing of patients. Further observation of MDT 
usage is required, considering national health guidelines, to better understand move-
ment towards personalized cancer management.
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bAckgROund: The high cost of VEGF-targeted anti-angiogenic therapies within a 
financially strained health-system, makes reimbursement decisions a potentially lim-
iting factor for new compounds. Failure to demonstrate adequate clinical benefit and 
cost-effectiveness in HER-2 negative metastatic breast cancer resulted in significant 
regulatory and health technology assessment (HTA) challenges. There is increasing 
expectation for new drugs to have companion diagnostics that identify likely patient 
responders, with growing support for using biomarkers to inform treatment deci-
sions Objectives: The purpose of this study was to critically examine published lit-
erature on trials incorporating biomarkers related to VEGF inhibition across different 
cancer indications, to explore their value as predictive, prognostic, pharmacological 
or surrogate response biomarkers MethOds: A search with a strict set of inclusion 
criteria was used to review the current literature. Information was gathered for 13 
biomarkers that have been explored for anti-VEGF therapy and a database was com-
piled housing raw experimental data for comparison. Each biomarker was critically 
evaluated and ranked accordingly, to validate their potential as predictive, prognostic, 
pharmacodynamic and surrogate endpoint markers for bevacizumab-based therapies, 
with consideration for likely regulatory, clinical and payer acceptance. Results: A 
total of 222 published studies were incorporated into the analysis. Plasma VEGF-A, 
PlGF and soluble VEGFR-1/VEGFR-2 demonstrated value as pharmacodynamic bio-
markers with limited prognostic value. CECs and CA19-9 showed prognostic and 
predictive value under restricted indications. Blood pressure demonstrated superior-
ity in its ability to predict response to bevacizumab. cOnclusiOns: The evidence 
suggests the incorporation of biomarkers in clinical trial design must be tailored to 
the drug and the cancer indication to which the therapy is applied. The potential for 
blood pressure as a biomarker of response to bevacizumab has been highlighted. 
Bevacizumab-induced hypertension should therefore be considered as a key candi-
date for future biomarker-driven trials, increasing the likelihood of test-treatment 
acceptance by key regulatory and HTA stakeholders.
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year or $49.0M/year nationally. cOnclusiOns: Differences in study design should 
be addressed when conducting an ITC. The evidence from this ITC shows that abira-
terone and enzalutamide have similar efficacy in OS in mCRPC post chemotherapy. 
However, abiraterone is cost saving compared to enzalutamide in this analysis.
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Objectives: Information about acute myeloid leukaemia (AML), including the 
costs of treatment and survival-estimates, are usually derived from clinical trial 
data. However, it is not known whether this information is generalizable to non-
trial patients. This study was carried out to evaluate the differences in medical costs 
and survival between trial and non-trial patients with AML; and hence assess the 
external validity of trial data to the general patient population. MethOds: The 
Haematological Malignancy Research Network (HMRN, www.hmrn.org) is an estab-
lished population-based patient cohort that registers around 2000 newly diagnosed 
patients each year. All adults (≥ 18) newly diagnosed with AML between September 
2004 and August 2007 and treated with induction intent were included. Patients were 
followed until August 2012, and the comparative outcomes were medical costs and 
survival. Standard statistical analyses were used to measure unadjusted difference 
in outcomes, and propensity score analyses were applied to measure differences by 
adjusting for baseline imbalance in pre-treatment characteristics between trial and 
non-trial patients. Results: Overall, 173 patients treated with induction intent were 
included, of which 106 were trial and 67 non-trial. Trial participation was associated 
with younger age, fewer comorbidities, better prognosis, and being treated at teach-
ing hospitals. Before controlling for patients’ characteristics, trial patients had better 
survival and incurred higher costs (p< .0001 for both). After controlling for patients’ 
characteristics by carrying out propensity score analyses, these differences remained 
significant in both survival (median survival 28.7 vs. 8 months; p< .0001) and medical 
costs (mean costs £84,497 vs. £49,624; p< .0001). cOnclusiOns: For AML patients 
treated with induction intent, significant differences were observed in treatment costs 
and survival according to trial status, both before and after controlling for patients’ 
pre-treatment characteristics. Data generated solely from clinical trials may therefore 
not be generalizable to non-trial patients and should be treated with some caution 
when used to facilitate decision-making.
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Objectives: To review the data available on excision margins following breast-
conserving therapy (BCT), focusing on definitions of positive and clear margins, per-
centage of operations resulting in positive margins, the effect of positive margins on 
future treatment, and the relationship between positive margins and disease-free 
and overall survival. MethOds: Targeted searches of PubMed were conducted using 
a predefined search strategy. Data from robust systematic reviews and/or meta-anal-
yses were given priority. Results: Definitions of positive and negative margins are 
variable, but typically a clear margin of 2 mm is considered acceptable. Most studies 
indicate positive margins in 20%-40% of patients after wide local excision. Guidelines 
recommend that patients with positive margins after BCT undergo repeat surgery, 
and in surveys, most physicians said they would recommend re-excision when there 
is tumour within 1 mm of the margin. In the identified studies, 20%-30% of patients 
underwent re-excision and approximately 2% had multiple re-excisions (two or more); 
10%-15% of patients who initially had lumpectomy later had a mastectomy. There 
is a significant association between margin status and local recurrence (in a recent 
meta-analysis, the odds ratio was 2.42 for positive vs. negative margin status; 95% 
confidence interval, 1.94-3.02; P< 0.001). However, among patients with a clear margin, 
width is not clearly related to risk of local recurrence. Four studies that assessed the 
effect of margin status on overall or disease-specific survival were identified, three 
reported a significant association (e.g., cause-specific survival at 12 years significantly 
associated with margin status, P< 0.001). cOnclusiOns: Definition of adequate mar-
gins remains controversial. None-the-less, final margin status is a key prognostic 
factor following BCT. The data identified suggest that an intervention that reduces 
the rates of positive margins during BCT may have the potential to improve outcomes 
and reduce the burden on patients and health care providers.
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Objectives: This research was conducted during a review of the manufacturer’s 
submission (MS) to the NICE Single Technology Appraisal programme for beva-
cizumab, a vascular endothelial growth factor (VEGF) inhibitor. Bevacizumab in 
combination with gemcitabine/carboplatin has recently been licensed for use in 
patients with platinum-sensitive or partially platinum-sensitive recurrent advanced 
ovarian cancer. This research compared this new triple therapy with treatments 
used in clinical practice in the UK: platinum monotherapy, gemcitabine/carboplatin, 
paclitaxel/carboplatin, pegylated liposomal doxorubicin hydrochloride (PLDH)/car-
boplatin. MethOds: Randomised controlled trials (RCTs) for inclusion were identi-
fied using the MS for bevacizumab. RCTs were assessed for comparability based on 
patient population, disease severity, platinum sensitivity, and treatments received. 
An MTC was conducted using a Bayesian Markov chain Monte Carlo simulation. 
or 500mg. The indirect analysis did not show a statistically significant difference in 
OS between everolimus compared with fulvestrant.
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Objectives: Patients with mRCC and a good performance status typically receive 
an anti-VEGFR TKI (sunitinib or pazopanib) as initial therapy. Upon disease progres-
sion or intolerance, there are four orally-administered agents approved in the 2nd 
- line setting (including cytokine-refractory). However, head to head comparative 
trial data are limited. In the absence of such data, mixed treatment comparison 
(MTC) models are a widely accepted statistical method for generating comparative 
effectiveness information. In this study, an indirect comparison on the safety and 
efficacy was undertaken between axitinib, sorafenib, pazopanib and everolimus 
for 2nd - line therapy in advanced RCC. MethOds: A systematic review of major 
databases was conducted from January 2005 to June 2013 for randomized controlled 
trials evaluating at least one of the four agents in 2nd- line mRCC. Bayesian MTC 
models were fitted to assess comparative effectiveness based on multiple endpoints: 
tumour response, progression free survival (PFS), grade III/IV toxicities such as diar-
rhea, fatigue, hand foot skin reaction, rash and stomatitis as well as treatment 
discontinuations. Results: A total of four randomized trials meeting the inclusion 
criteria were appropriate for the statistical pooling exercise. All four agents seem 
able to induce tumour shrinkage and provide patients with a clinically meaningful 
PFS benefit. Axitinib was superior to pazopanib (HR = 0.64; 95%Crl: 0.42 to 0.96) and 
sorafenib (HR = 0.70; 95%Crl: 0.57 to 0.87) in terms of PFS. However, patients receiv-
ing axitinib would be at an elevated risk for fatigue and to a lesser extent, stoma-
titis. cOnclusiOns: Keeping in the mind the caveats associated with cross-trial 
comparisons, axitinib appears to provide superior PFS benefits relative to pazopanib 
and sorafenib. However, this is at a cost of a higher frequency of some dose-limiting 
toxicities. Everolimus, an mTor inhibitor, is mechanistically distinct from the other 
agents evaluated and would be a useful option post anti-VEGFR TKI failure.
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Objectives: To perform a systematic review and meta-analysis of all randomized 
controlled trials comparing the efficacy of targeted therapy to conventional CT in 
patients with metastatic Triple-Negative Breast Cancer (TNBC). MethOds: Several 
databases were searched, including MEDLINE, EMBASE, LILACS, and CENTRAL. The 
primary endpoint was progression-free survival (PFS). We performed a meta-analysis 
(MA) of the published data. The results were expressed as Hazard Ratio (HR) or Risk 
Ratio (RR), with their corresponding 95% confidence intervals (CI 95%). Results: 
The final analysis included 12 trials comprising 2,054 patients with TNBC. It was 
evidenced studies with conventional CT plus targeted therapy including bevacizumab 
(Bev), sorafenib (Sor), cetuximab and iniparib. The PFS was higher in patients who 
received Bev plus CT compared to CT alone in previously untreated patients with 
TNBC (fixed effect: HR= 0.62; CI 95%= 0.51-0.75; p< 0.00001). The PFS was also higher 
in one study with Bev plus CT in previously treated patients (fixed effect: HR= 0.49; 
CI 95%= 0.33-0.74; p= 0.0006). Sor plus CT was available in first-line and second-line. 
The PFS was higher in the group with Sor versus CT alone (fixed effect: HR= 0.69; CI 
95%= 0.49-0.98; p= 0.04) and iniparib plus CT (fixed effect: HR= 0.75; CI 95%= 0.62-0.90; 
p= 0.002). cOnclusiOns: Bev, Sor and iniparib, when associated with the conven-
tional CT, demonstrated gains in the PFS of patients with TNBC.
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Objectives: Abiraterone and enzalutamide are two new treatment options for 
patients with mCRPC after docetaxel-based chemotherapy. This study aims to 
understand the relative clinical and economic value of these therapies. MethOds: 
Two pivotal clinical trials were conducted to evaluate abiraterone and enzalutamide 
in post-docetaxel treatment of mCRPC: Study COU-AA-301 for abiraterone and the 
AFFIRM trial for enzalutamide. The PICO (population, intervention, comparison, and 
outcomes) construct was employed to assess the comparability of the trials, followed 
by an indirect treatment comparison (ITC) using the Bucher method and a mix treat-
ment comparison using Bayesian statistics. An economic evaluation was performed 
based on the ITC results. Results: Several key differences were identified between 
the COU-AA-301 and AFFIRM trials. First, the studies used different comparators. 
Abiraterone plus prednisone was compared with prednisone alone, while enzaluta-
mide was compared with placebo. Second, the endpoints rPFS, PSA progression, and 
PSA response were defined differently between trials, and thus were not included in 
the analysis. To address the difference in comparators, the ITC was performed using 
data from COU-AA-301 and subjects receiving corticosteroids concurrently in the 
AFFIRM trial. OS was significantly improved with both abiraterone and enzalutamide 
(3.9 and 3.2 months respectively). The ITC results were HR = 0.949 (95% CI: 0.712-1.26) 
for abiraterone versus enzalutamide using the Bucher method, and HR = 0.948 (95% CI: 
0.711-1.26) using the Bayesian method. Using the US price for abiraterone and enza-
lutamide (approved in the US only), and assuming 25% of patients received therapy 
following docetaxel, cost savings from using abiraterone would be > $10K/patient/
